Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Choroidal Neovascularization: early-phase trial registry
1 of 8 indexed Choroidal Neovascularization trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 1 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Choroidal Neovascularization: 8 US clinical trials tracked, 1 recruiting.
Choroidal Neovascularization is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 2 of these trials.
Enrollment posture brief
Registry condition choroidal-neovascularization
OPEN 1 | RECR 13% | LATE 0 | EARLY 5 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)
Choroidal Neovascularization lists 1 open slots (13% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Choroidal Neovascularization on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Choroidal Neovascularization is recruiting below its size-band peers.
1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Choroidal Neovascularization research.
Johns Hopkins University accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Choroidal Neovascularization trials plan to enrol fewer than 100 people.
Median target enrolment is 98 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Choroidal Neovascularization research is mostly interventional.
6 interventional and 2 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie
NCT04704921
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Quark Pharmaceuticals
NCT01445899
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
Sequenom
NCT01880788
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
Johns Hopkins University
NCT00417846
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Iconic Therapeutics
NCT02358889
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
Vision Research Foundation
NCT01256632
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
Retinal Consultants Medical Group
NCT00426998
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Johns Hopkins University
NCT00363168
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Choroidal Neovascularization records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Choroidal Neovascularization trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Choroidal Neovascularization page
8 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Choroidal Neovascularization trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins University sponsors the most Choroidal Neovascularization trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Choroidal Neovascularization condition card totals 8 registered trials; most-linked intervention Ranibizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.